BASELINE METABOLIC TUMOR VOLUME AND IPS PREDICT ABVD FAILURE IN ADVANCED-STAGE HODGKIN LYMPHOMA WITH A NEGATIVE INTERIM PET SCAN AFTER 2 CHEMOTHERAPY CYCLES. A RETROSPECTIVE ANALYSIS FROM THE GITIL/FIL HD0607 TRIAL